Kornimate/medical-research-clean huggingface dataset:
chd patient's concern on cardiac rehabilitation

Conditions: Coronary Heart Disease; Cardiac Rehabilitation

Summary: our study focuses on the question about primary cardiac rehabilitation (cr) patients with coronary heart disease are concerned about demonstrating the association between the patients' view of cr and social associated factors. in our study, all participants are invited to choose at least 1 question in 15 questions or provide their questions regarding their doubt about the cr after filling in their personal information. the selectable questions can be categorized into five titles: the content or purpose of cr, the method of cr, the advantage of cr, the adverse effect of cr, and the expenditure of cr.


Eligibility criteria:
inclusion criteria: * age \>18 years old * patients diagnosed as coronary heart disease * able to participate in cardiac rehabilitation after medical judgments for the first time * understand the questionnaire content * agree to participant in the study and provide the written informed consent exclusion criteria: * unable to complete the questionnaire * patients who aren't willing or refuse to participate in the trial

Keywords: cardiac rehabilitation coronary heart disease social-psychological factor
dexamethasone for cardiac surgery trial

Conditions: Systemic Inflammatory Response Syndrome; Cardiac Diseases; Postoperative Complications

Summary: this is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. the primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.


Eligibility criteria:
inclusion criteria: * all types of cardiac surgery in which cardiopulmonary bypass is used exclusion criteria: * age under 18 years * life-expectancy \< 6 months * emergency operations * re-operations within the same admission

Keywords: heart surgery cardiopulmonary bypass systemic inflammatory response syndrome (sirs)
a study of how cagrisema works on appetite in people with excess body weight

Conditions: Overweight; Obesity

Summary: part a: the study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake. participants will not get any medicine and will be in a group that will be compared to another group receiving a weight-loss medicine. the study will last for about 6 months. part b: the study will look at how cagrisema works on participants appetite and energy intake and will be compared with a ''dummy'' medicine. the study will also look at how participants brain works when participants take the medicine. participants will either get cagrisema or ''dummy'' medicine.


Eligibility criteria:
inclusion criteria: * male or female * aged 18-65 years (both inclusive) at the time of signing informed consent * right-handed as evaluated by the edinburgh handedness inventory * body weight less than or equal to 180 kilogram at screening for part a: * a score of 7 or less on the 16-item disinhibition subscale of the three factor eating questionnaire * body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) at screening for part b: * a score of 8 or more on the 16-item disinhibition subscale of the three factor eating questionnaire * body mass index equal to or above 27.0 kilogram per meter square. overweight should be due to excess adipose tissue, as judged by the investigator exclusion criteria: * contraindication for magnetic resonance scanning for part b: * glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) at screening * history of type 1 or type 2 diabetes mellitus
evaluation of predictive markers for toxicity and efficacy in patients with mccrcc treated by anti-vegf therapy

Conditions: Clear-cell Metastatic Renal Cell Carcinoma

Summary: the purpose of this study is to assess whether certain metabonomics and/or lipidomics features in correlation with pharmacokinetics before, during and after treatment with sunitinib or pazopanib in first line can predict toxicity and efficacy of sunitinib or pazopanib in metastatic clear cell renal cell carcinoma patients.


Eligibility criteria:
inclusion criteria: * woman or man ≥ 18 years old, histologically proven metastatic clear cell (or al least clear cell predominant) rcc, * good or intermediate risk according to mskcc-criteria, subjects falling into conditions for reimbursement of sunitinib or pazopanib in the context of mrcc, * measurable disease based on recist criteria (version 1.1) , subject has given voluntary written informed consent, * subject is in the investigator's opinion, willing and able to comply with the protocol requirements, subject has an ecog ≤ 2, * subject with a life expectancy ≥ 3 months, * concurrent treatment with bisphosphonates and denosumab is allowed however it should have been started before screening of the study. if possible starting new medications between the baseline metabolo- and lipidomotype- and the first metabolo- and lipidomotypeanalysis should be avoided, * subjects having recovered from side effects from previous therapies to a grade 1 ctc vs 4.0 criteria exclusion criteria: * patients with non-clear cell rcc and/or with sarcomatoid differentiation, * patients presenting any other type of cancer disease within 5 years from inclusion into this study; in the absence of cervical cancer or basocellular carcinoma, patients with uncontrolled arterial hypertension, * patients with uncontrolled hypo- or hyperthyroidism, * patient had major surgery within 4 weeks before enrolment, * patient with myocardial infarction within 6 months prior enrolment or with nhya class iii otr iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmia or electrocardiographic evidence of acute ischemia or active conduction system abnormalities, * patient has another serious medical condition that could potentially interfere with the completion of study, * sero-positive for hiv, subject known to be hepatitis b surface antigen positive or who has an active hepatitis c infection, * subject has an active systemic infection requiring treatment, * female subject is pregnant or breast feeding, subject enrolled in another clinical trial and/or receiving an investigational agent.
efficacy of acceptance and commitment therapy on impulsivity and suicidality among clients with bipolar disorders

Conditions: Bipolar Disorder

Summary: psychiatric nurses face a huge challenge in predicting and preventing suicide behaviour in their patients with bipolar disorders, but it may also be one of the most accurate measures of how well their clinical care is working. in addition to, high impulsivity scores are associated with increased overall functional impairment, a higher number of episodes with early onset, and a higher number of past suicide attempts, as well as increased substance intake. thus, this study aimed at evaluating the efficacy acceptance and commitment therapy on impulsivity and suicidality among bipolar clients. research hypnosis * clients who engaged in acceptance and commitment therapy had less impulsivity than the control group. * clients who engaged in acceptance and commitment therapy had less suicidality than the control group.


Eligibility criteria:
inclusion criteria: * clients had to be at least 18 years old * able to converse intelligibly and meaningfully * read and write * have an illness that hadn't lasted more than 10 years to assure the client's functionality * ready to take part in the study. exclusion criteria: * clients who demonstrated psychotic symptoms * attended another group sessions * were intoxicated or under the influence of alcohol * had any comorbidity were excluded from this study

Keywords: acceptance and commitment therapy bipolar disorders impulsivity suicidality
trazodone on osa endotypes

Conditions: Obstructive Sleep Apnea

Summary: obstructive sleep apnea (osa) is common and has major health implications but treatment options are limited. some osa patients with low arousal threshold wake up prematurely during an obstructive event and do not have time for spontaneous upper airway (ua) dilator muscle recruitment. as a consequence they are exposed to apnea and hypopnea cycling. in this protocol the investigators will test the effect of trazodone administered before sleep on osa traits and osa severity during sleep.

two overnight home sleep studies will be performed: a drug night and a placebo night. the patient will breath spontaneously (without cpap) for both nights. on the study nights, subjects be instrumented with a full polygraphy for monitoring sleep, and respiratory events. trazodone 100 mg will be given 30 min before lights out. at least four hours of sleep with high quality signal acquisition will be required for a study to be judged adequate. after the first overnight study is completed, there will be a one-week washout period prior to crossing over to the other treatment.

Eligibility criteria:
inclusion criteria: * moderate-to-severe osa (ahi ≥ 15 events/hr) exclusion criteria: * all participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements. * use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid). * use of snris/ssris. * conditions likely to affect osa physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition. * sleep disordered breathing or respiratory disorders other than obstructive sleep apnea: * other sleep disorders: periodic limb movements (periodic limb movement arousal index \> 10/hr), narcolepsy, or parasomnias. * hypersensitivity to the study drug (angioedema or urticaria) * contraindications to daw2020 * use of medications that lengthen qtc interval * hypokaliemia, hypomagnesemia, uncontrolled thyroid disease * severe claustrophobia.
applied forces during neonatal face mask ventilation with different face-mask air cushion volumes

Conditions: Positive Pressure Ventilation; Preterm Infants; Apnea

Summary: positive pressure ventilation (ppv) is the most important intervention in neonatal resuscitation. during ppv, it is important to hold the face-mask with care, as applying excessive pressure could cause injury to the infant, while insufficient pressure could be a contributor of mask leak and reduced effective ventilation. application of positive pressure to face structures may trigger a vagally mediated reflex via the trigeminal nerve that innervates the skin of the face leading to apnoea and a decrease in heart rate (tcr, trigeminal-cardiac reflex). in neonatal manikins, ventilation with a partially or fully inflated face mask does not seem to result in differences in mask leak. the force exerted by providers to improve mask seal might result in pressure lesions and in the elicitation of the trigeminal-cardiac reflex. however, information about the applied forces is unknown.


Eligibility criteria:
inclusion criteria: * level iii nicu consultants and pediatric residents exclusion criteria: * none
retrospective evaluation of ketamine effectiveness for the treatment of acute battlefield related pain

Conditions: Pain, Acute; Analgesia; Amputation, Traumatic; Post Traumatic Stress Disorder; Trauma, Brain

Summary: using a retrospective review of records, we will conduct a multivariate analysis to examine the relationship between exposure to ketamine, as an analgesic agent in combat related trauma care, the use of additional opioid pain medications, and patient reported pain levels.

this is a retrospective study to determine if there is a relationship between intravenous infusion of ketamine given for analgesia and the use of additional opioid pain medications and patient reported pain levels before and during ketamine usage. the investigator anticipates that records of up to 700 subjects will be reviewed for eligibility. the time period 24 hours before the initial ketamine therapy is initiated along with 24 \& 48 hours after the start of ketamine therapy will be the time periods examined. the average/minimum/maximum pain scores during these time periods will be used. medication usage will be calculated over the 24 hour time periods. this protocol is presented as an initial step in exploring the possible relationship between the administration of ketamine as an analgesic agent, the potential reduction in pain medications, and the potential reduction of pain levels. with this the goals/objectives are as follows: objectives 1. to compare morphine consumption in battlefield injured patients with acute pain 24 hours before the initiation of a ketamine infusion to the subsequent 48 hours following the start of infusion. 2. to compare average/minimum/maximum pain scores in battlefield injured patients with acute pain 24 hours before the initiation of a ketamine infusion to the subsequent 48 hours following the start of infusion. 3. to describe the pain trajectory in battlefield injured patients with acute pain after the initiation of ketamine infusions. 4. to measure the absolute and proportional incidence of ketamine associated side effects in battlefield injured patients with acute pain following the initiation of ketamine infusions.

Eligibility criteria:
inclusion criteria: * battlefield injured from january 2007 to december 2013 * prescribed a ketamine infusion for acute pain * awake, alert (non intubated/sedated), and able to report pain scores 24 hours prior to the start of infusion and up to 48 hours following infusion exclusion criteria: * patients who did not receive an injury in theater and did not receive ketamine while being treated by the aps or wrnmmc/wramc hospital staff * no continuous perineural catheter or epidural placement while on ketamine infusion * less than 18 years old

Keywords: battlefield injury ketamine infusion regional anesthesia opioids
an observational study investigating the treatment satisfaction of atopic dermatitis patients who have switched to ointment (w/o emulsion) formulation of very strong class topical corticosteroids

Conditions: Dermatitis, Atopic

Summary: this study intends to investigate patient satisfaction of treatment with ointment (w/o emulsion) formulations of potency class ii topical corticosteroids (tcs) for atopic dermatitis (ad) patients in japan. objectives include measuring patient satisfaction, treatment adherence, itchiness, and ad severity scores.


Eligibility criteria:
inclusion criteria: * female and male patients with a diagnosis of atopic dermatitis who are treated with fatty ointment potency class ii (very strong class) tcs * patients who are scheduled to change the formulation of the potency class ii tc from fatty ointment to ointment (water in oil; water per oil emulsion) as per investigator's routine treatment practice * patients who are aged over 20 * patients who are able to understand and sign a written informed consent exclusion criteria: -patients participating in an investigational program with interventions outside of routine clinical practice * patients with any contraindication to tcs * patients who are regarded as ineligible by the investigator * patients who are pregnant or breastfeeding * for period 2 (spring-summer), patients enrolled in the period 1
valsartan/hydrochlorothiazide combination in hypertensive patients not controlled with valsartan alone

Conditions: Hypertension

Summary: this study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication.


Eligibility criteria:
inclusion criteria: * patients with mild to moderate hypertension exclusion criteria: * severe hypertension * history of stroke, myocardial infarction, heart failure, chest pain, abnormal heart rhythm * liver, kidney, or pancreas disease * insulin dependent diabetes * allergy to certain medications used to treat high blood pressure other protocol-defined exclusion criteria may apply.

Keywords: hypertension high blood pressure valsartan hydrochlorothiazide
sorafenib-induced hand- foot skin reaction treatment

Conditions: Hand-foot Skin Reaction; Rash

Summary: the purpose of this study is to evaluate treatments for a rash caused by sorafenib.

this study will compare compare the effectiveness of four creams (urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and udderly smooth® udder cream) in treating hand-foot skin reaction (hfsr), a rash caused by sorafenib.

Eligibility criteria:
inclusion criteria: * patients receiving sorafenib as monotherapy or in combination if other agents are not known to cause hfsr. * subjects must be 18 years or older. * patients must provide written informed consent to participate in the study. * women of childbearing potential and men must be willing to use an effective method of contraception while participating in this study and for at least two weeks after completing treatment in the study. * women in this study need to have a negative urine pregnancy test before starting study medications. exclusion criteria: * patients simultaneously taking another anti-cancer agent or combination of anti-cancer agents known to cause hand foot syndrome (pegylated doxorubicin, 5-fluorouracil, cytarabine). * patients with an active dermatological condition due to previous chemotherapy or biologic therapy affecting the hands. * patients with pre-existing dermatological condition affecting the hands or feet. * women who have a positive pregnancy test or are lactating.

Keywords: sorafenib rash hand foot skin reaction
involved field irradiation (ifi) versus elective nodal irradiation (eni) for esophageal cancer

Conditions: Esophageal Squamous Cell Carcinoma

Summary: this study examines contrast advantages and disadvantages of elective or prophylactic nodal irradiation in the treatment of esophageal cancer with three-dimensional conformed radiotherapy.

esophageal lymph node drainage area is rich, according to different sites, easy to metastasis to different regions. for patient underwent concurrent chemoradiotherapy, how reasonable design the clinical target volume of lymph node drainage area has always been controversial, one is to irradiate positive lymph nodes only, the other is to irradiate the easier involved lymph node area according to different sites, in order to contrast advantages and disadvantages of the two kind of target area design，so the study was designed.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 and ≤ 80 2. ecog performance status 0-2 3. weight is not less than 90% of it before treatment 4. histologically proven primary thoracic esophageal squamous cell carcinoma previously untreated stage i-iii 5. chest and abdominal contrast enhanced ct within 2 weeks prior to registration(pet/ct scan is selective) 6. wbc ≥ 4.0x109/l ,absolute neutrophil count (anc) ≥ 2.0x109/l 7. platelets ≥ 100x109/l 8. hemoglobin ≥ 90g/l(without blood transfusion) 9. ast (sgot)/alt (sgpt) ≤ 2.5 x upper limit of normal, bilirubin ≤ 1.5 x upper limit of normal 10. creatinine ≤ 1.5 x upper limit of normal 11. sign study-specific informed consent prior to study entry - exclusion criteria: 1. multiple primary esophageal tumors 2. prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible). 3. severe, active comorbidity, defined as follows: * unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months * transmural myocardial infarction within the last 6 months * acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration * acquired immune deficiency syndrome (aids) based upon current cdc definition; note, however, that hiv testing is not required for entry into this protocol. the need to exclude patients with aids from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive. 4. pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception. 5. prior systemic chemotherapy, prior radiation therapy or prior target drug therapy

Keywords: esophageal squamous cell carcinoma concurrent chemoradiotherapy clinical target volume safety prognosis
a study to evaluate deucravacitinib in participants with moderate-to-severe plaque psoriasis in germany

Conditions: Plaque Psoriasis

Summary: the purpose of this observational study is to describe the effectiveness of deucravacitinib treatment and quality of life in adults with moderate-to-severe plaque psoriasis in routine clinical practice in germany over a 5-year period


Eligibility criteria:
inclusion criteria: * patients with a physician-reported diagnosis of moderate-to-severe plaque psoriasis initiating deucravacitinib according to approved label in the european union * the decision upon treatment with deucravacitinib must have been made before enrollment and independently of this non-interventional observational study * patient is at least 18 years of age at the time of treatment decision * patient provided written informed consent to participate in the study exclusion criteria: * any contraindications according to the approved deucravacitinib summary of product characteristics * prior treatment with deucravacitinib * simultaneous participation in an interventional clinical trial for moderate-to-severe psoriasis
phase i/ii study of high-dose acyclovir for central nervous system or disseminated neonatal herpes simplex virus infection

Conditions: Herpes Simplex

Summary: objectives: i. evaluate whether high-dose acyclovir decreases acute and long-term morbidity and mortality in neonates with central nervous system or disseminated herpes simplex virus (hsv) infection. ii. evaluate whether high-dose acyclovir is safe and tolerated in the newborn. iii. assess resistance to antiviral medication. iv. amplify disease classification for the purpose of predicting prognosis. v. assess any changes in viral excretion patterns. vi. evaluate whether antigens and antibodies specific for hsv glycoproteins within the cerebrospinal fluid (csf) predict long-term neurologic outcome. vii. evaluate whether specific antigens and antibodies in the csf appear late after treatment and are indicative of insidious reactivation of virus in the brain.

protocol outline: neonates are treated with intravenous acyclovir for 21 days. patients are followed at day 28, and at 6, 12, 24, 36, and 48 months.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- herpes simplex virus infection that is disseminated or localized to the central nervous system virologically confirmed by 1 of the following methods: * tissue culture * monoclonal antibody staining * electron microscopy --prior/concurrent therapy-- no concurrent antiviral therapy --patient characteristics-- life expectancy: no imminent demise birth weight at least 1200 g gestational age over 32 weeks

Keywords: herpes simplex virus infection herpesvirus infection immunologic disorders and infectious disorders rare disease viral infection